Abbott Laboratories
Novel indolinone A-432411 shows promise as antitumor agent
Published in Cancer Law Weekly, June 18th, 2005
"Microtubules are among the most successful targets for anticancer therapies and for the development of new anticancer drugs," scientists in the United States explained. "A-432411 is a novel small molecule that destabilizes microtubules at high concentration and disrupts normal spindle formation at low concentration."
"A-432411 is an indolinone that is structurally different from other known synthetic microtubule inhibitors," noted Z.H. Chen and colleagues at Abbott Laboratories. "This compound is efficacious against a variety of human cancer cell lines, including...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Law Weekly
Source: Cancer Law Weekly (2005-06-18)
More Articles from Cancer Law Weekly
- Apoxis
Swiss company wins award for cancer drug development - Coley Pharmaceutical Group, Inc.
Waiting period expiring for CPG 7909 licensing agreement with Pfizer - National Taiwan University Hospital
Vascular indices predict liver cancer responsiveness to thalidomide - OncoMethylome Sciences
License for silencing several tumor-suppressor genes in prostate cancer granted - St. Jude Children's Research Hospital
Scientists join to develop laboratory model of immune system - University of Texas, Galveston
Research in prostate cancer provides new insights - More from this issue of Cancer Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
